IBIO: Long-acting antibody pipeline targets obesity gaps, IND filings, first-in-human trials ahead

 Management outlined a portfolio of long-acting antibody programs targeting obesity and related diseases, leveraging AI-driven discovery and a dual Australia-U.S. regulatory path. Key milestones include IND filings, first-in-human trials, and strategic partnerships, supported by a strong cash position.

Based on iBio, Inc. [IBIO] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 4 2025

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2434288:0-ibio-long-acting-antibody-pipeline-targets-obesity-gaps-with-ind-filings-and-first-in-human-trials-ahead/